Merck & Co. (MRK) is close to an approximately $6 billion all-cash deal to buy US biotech firm Terns Pharmaceuticals (TERN) as it seeks to boost its drug pipeline ahead of cancer treatment Keytruda’s patent expiry, the Financial Times reported.

The talks